Revvity Signals || Signals One™

EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

  • Articles

    Gene Therapy: Breakthrough Treatments for Rare Diseases

    The idea of gene therapy is radically changing the sphere of medicine with the possibilities to cure the patients with the rare hereditary diseases These diseases which are usually brought about by the alteration of the sequence

    Chiral Biosensors: Precision Tools for Safer Drugs

    The pharmaceutical industry has long been recognised the profound implications of chirality in drug design and development Enantiomers mirrorimage isomers of a chiral molecule show dramatically distinct pharmacokinetic PK and pharmacodynamic PD profiles One may be therapeutically active while its counterpart could be inactive or harmful As a result the precise detection discrimination and quantifi...

    Understanding Pharmacodynamics: The Science behind Drug Action Mechanisms

    In the complicated world of pharmacology pharmacodynamics is also a place that is a bridge between chemistry and physiology Drugs do something somewhere and this explains how they do it In a simple way pharmacodynamics studies the action of drugs the effects of drugs in terms of their biochemical and physiological effects and how the effects are generated

    Innovative Pricing Models in the EU: Making Medicines Affordable for All

    Pricing policies are important determinants in delivering sufficiently cheap medicines in all the member nations of the EU High costs of meeting the required medical care together with arising independent differentiated technological improvements have rendered exhausted pricing structures as uncompetitive tools for fairness New mechanisms of pricing have been introduced

    Exploring the Benefits of Bioassay in Pharmacology

    Pharmacology the study of drugs and their effects on living organisms is a multifaceted field crucial to the development and improvement of pharmaceuticals Bioassay a method that assesses the potency of substances

    Fundamentals of Clinical Pharmacology: Understanding Drug Actions and Ensuring Safety

    Clinical pharmacology offers the interface between the philosophies of pharmacology and its application in the actual sense in patient care Fundamentally it is the science which examines the activities of drugs how drugs communicate with biological systems and how such communications result in treatment outcomes or adverse events Clinical pharmacology principles are needed to make sense of how m...

TOP ARTICLES

  • 1

    Chiral Biosensors: Precision Tools for Safer Drugs

    Dr. Selvakumar Kanthiah

    Dr. Valliappan Kannappan

    In drug development, identifying the right mirror-image molecule - called an enantiomer - can be the difference between a life-saving treatment and unwanted side effects. Chiral biosensors are revolut...

  • 4

    Exploring the Benefits of Bioassay in Pharmacology

    Harry Callum

    Bioassays, integral to pharmacology, assess drug effects on living organisms. In vitro assays use isolated cells, aiding early drug screening, mechanism understanding, and target validation. In vivo a...

press releases Read more...

Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome

Orvida Pharma a clinicalstage biotechnology company developing first and bestinclass treatments for rare and severe genetic skin diseases today announced that the US Food and Drug Administration FDA has accepted KM ontivatrep the Companys lead oral investigational therapy for Olmsted syndrome

Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026

Sapreme Therapeutics a biotechnology company developing nextgeneration RNA therapeutics for patients with genetically driven diseases today announces the oral presentation of new preclinical data from its lead Duchenne muscular dystrophy DMD programme SPM at the nd Annual Meeting of the Oligonucleot...

Oorja Bio Announces Initiation of ORBIT-IPF Phase 2 Clinical Trial Evaluating ORJ-001 for the Treatment of Idiopathic Pulmonary Fibrosis

Oorja Bio Inc a clinicalstage biopharmaceutical company developing groundbreaking therapies for fibrotic and cardiopulmonary diseases today announced that the first patient has been screened in its ORBITIPF Phase clinical trial evaluating ORJ for the treatment of idiopathic pulmonary fibrosis

Tenvie Therapeutics Announces First Subject Dosed in Phase 1 Trial of TNV313, Expanding Its Fully CNS-Penetrant NLRP3 Franchise

Tenvie Therapeutics a clinicalstage biotechnology company developing precisionengineered small molecule therapies to transform the treatment of neurological and peripheral diseases today announced the first subject dosed in a Phase clinical study evaluating TNV a fully CNSpenetrant small molecule i...

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

Pharma Manufacturing & Automation Convention 2026

Novotel Hyderabad Airport, Ind...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

LATEST NEWS Read more...

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

Vir Biotechnology Inc announced a collaboration and license agreement with Gilead to discover and engineer three novel PROXTEN dualmasked Tcell engager TCE development candidates targeting selected solid tumorassociated antigens Gilead will have an exclusive license to develop and commercialize

Genezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human Trial

Genezen a gene therapy contract development and manufacturing organization CDMO and Galibra Neuroscience a biotechnology company developing transformative therapies for rare neurological disorders today announced a manufacturing partnership to advance Galibras GAL program an AAVbased gene therapy fo...

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Zealand Pharma AS a biotechnology company transforming the future of metabolic health today announced a multitarget strategic collaboration with Generate Biomedicines Inc Under the collaboration the companies intend to design and develop multispecific protein therapeutics

Enodia Therapeutics announces research and licensing collaboration agreement with Pfizer to develop small molecules directed against Sec61

Enodia Therapeutics a biotech company specializing in the development of innovative therapies with small molecules for the selective degradation of proteins at the point of synthesis today announced the signing of a collaborative research and licensing agreement with Pfizer

Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio

Catalent Inc the leading global contract development and manufacturing organization CDMO dedicated to helping people live better and healthier lives and Mantra a consumer health company developing singleserve over the counter OTC oral gel products for everyday relief

Amphista Therapeutics Announces First Patient Dosed in AMX-883 Phase 1 Clinical Trial for Acute Myeloid Leukemia

Amphista Therapeutics Limited a leader in the discovery and development of noncereblon VHL targeted protein degradation TPD medicines today announced dosing of the first patient in a Phase trial for its lead candidate AMX Initiated following authorization from the US Food and Drug Administration i...